Affymax Inc. (AFFY)
Market Closed
11 Aug, 20:00
OTC PINK OTC PINK Primary $
0. 00
0
0%
$
56.23K Market Cap
0 P/E Ratio
- Div Yield
6,000 Volume
0 Eps
$ 0
Previous Close Want to track AFFY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
AFFY closed yesterday higher at $0, an increase of 0% from Monday's close, completing a monthly increase of 23.0769% or $0. Over the past 12 months, AFFY stock gained 100%.
AFFY pays dividends to its shareholders, with the most recent payment made on Dec 23, 2014. The next estimated payment will be in 23 Dec 2014 on Dec 23, 2014 for a total of $0.05.
The last earnings report, released on May 08, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Affymax Inc. (AFFY) FAQ
What is the stock price today?
The current price is $0.00.
On which exchange is it traded?
Affymax Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is AFFY.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 56.23K.
Has Affymax Inc. ever had a stock split?
No, there has never been a stock split.
Affymax Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jonathan Couchman CEO | OTC PINK Exchange | 00826A109 CUSIP |
| US Country | 2 Employees | 24 Dec 2014 Last Dividend | - Last Split | 15 Dec 2006 IPO Date |
Overview
Affymax, Inc. is a company with a history in the pharmaceutical industry that no longer has significant operational activities. Founded in 2001 and headquartered in New York, New York, Affymax was once engaged in the development of drugs aimed at improving the treatment of serious and often life-threatening conditions in the United States. However, it currently does not engage in any substantial operational activities, indicating a significant shift from its previous objectives in drug development.
Products and Services
Prior to its shift away from significant operations, Affymax, Inc. was involved in the following area:
- Drug Development: The main focus of Affymax's operations was on the development of innovative drugs intended to enhance the treatment options available for serious and often life-threatening conditions. This endeavor aimed to bring new therapeutic options to the market, addressing unmet medical needs within the healthcare sector. Despite the current status of the company indicating a halt in these activities, this past focus underscores a commitment to advancing medical treatments and improving patient outcomes.
Contact Information
Address: 630 Fifth Avenue
Phone: 650 812 8700
Website: https://www.affymax.com
